Drugs for disorders of the alimentary tract or the digestive system (A61P1)

A   Human necessities(312083)
A61P1                 Drugs for disorders of the alimentary tract or the digestive system(7081)
New benzoazepine derivative and its medical application // 2642783
FIELD: pharmacology.SUBSTANCE: invention relates to a new benzoazepine derivative of formula (I) or a pharmacologically acceptable salt thereof, wherein R1 represents a hydroxyl group, a lower alkoxy group or , where A is absent or a lower alkylene group which may be substituted by a lower alkyl group; R6 represents a hydrogen atom or a lower alkyl group; R7 represents a hydrogen atom, a hydroxyl group, a five-membered aromatic heterocyclic group containing 3 heteroatoms selected from nitrogen and oxygen which may be substituted by a lower alkyl group, a five-membered non-aromatic heterocyclic group containing one nitrogen atom which may be substituted by an oxo group or a carbamoyl group , which may be substituted by a lower alkyl group; R2 represents a hydrogen atom or a lower alkyl group; R3 is a lower alkyl group which may be substituted by 1 to 3 fluorine atoms or a halogen atom; R4 represents a lower alkoxy group which may be substituted by 1 to 3 halogen atoms, a five-membered aromatic monocyclic heterocyclic group or a five-membered non-aromatic monocyclic heterocyclic group (provided that each of these heterocyclic groups contains one nitrogen atom, two nitrogen atoms or one nitrogen atom and one oxygen atom in the ring, and may contain a lower alkyl group); and R5 represents a hydrogen atom, a lower alkyl group or a halogen atom. The invention also relates to a pharmaceutical composition based on a compound of the formula and intermediates of the formulas and .EFFECT: new benzoazepine derivatives having V2 receptor agonist activity are obtained.14 cl, 12 tbl, 128 ex

Inhibitor of hyaluronic acid decomposition including rosemary extract and retinol acetate // 2642672
FIELD: pharmacology.SUBSTANCE: hyaluronidase inhibitor includes rosemary extract and retinol acetate in the following ratio: 0.01 - 5 wt % parts of retinol acetate per 1 wt % part of rosemary extract. Means for external use on the skin to alleviate or prevent skin problems selected from the group consisting of skin aging, wrinkled skin, rough skin, dry and rough skin, acne and atopic dermatitis, including a hyaluronidase inhibitor. The cosmetic treatment method includes rosemary extract and retinol acetate application to the subject suffering from a decrease in the hyaluronic acid level, in the following proportion: 0.01-5 wt parts of retinol acetate per 1 wt % part of rosemary extract.EFFECT: agent has a synergistic activity of hyaluronidase inhibition.3 cl, 1 dwg
ethod for treatment of recurrent vulvovaginal candidiasis // 2642666
FIELD: medicine.SUBSTANCE: immunomodulatory therapy is administered by local action on the cervico-vaginal area with a drug containing sodium aminodihydrophthalazinedione, represented by the rectal suppositories Galavit, by introduction into the cervico-vaginal zone in successive doses of 100 mg overnight in three steps: the first preparatory phase of recovery of functional metabolic activity of cervical secret neutrophilic granulocytes by stimulation of their microbicidal activity by daily administration of the said drug with a course of 5 doses, one dose per day; the second stage of normalization of the monocyte-macrophagal system in the cervico-vaginal zone by enhancing phagocytosis using this drug with a course of 5 doses at a single dose with 48 hours pauses between them; the third stage of formation of a stable immune response in the cervico-vaginal zone at the local level by introduction of this drug with a course of 10 doses at a single dose with 72 hours pauses, and administration of a systemic antimycotic, which is itraconazole administered orally at a dose of 200 mg 1 dose daily, is performed at the third stage, starting with the administration of the 15th dose of Galavit.EFFECT: normalization of the local immune status, with preservation of a full-fledged immune response in the long-term period, a stable immunity is provided, with a reduction in the number of relapses and a reduction in the duration of treatment.3 cl, 2 tbl, 2 ex
ethod of treating inflammatory periodontal and oral mucosal diseases // 2642648
FIELD: medicine.SUBSTANCE: method of treating inflammatory periodontal and oral mucosal diseases include the elimination of acute and inflammatory processes in the acute stage, elimination of supragingival and subgingival dental deposits, surgical and orthopedic intervention if there is evidence; oral irrigation with ozonated mineral water, optionally hydromassage, irrigation, instillation and irrigation on disease sites of periodontal tissue and oral mucosa is held with 3.5-2.5% solution of bentonite in warmed up to 38-42° C ozonized mineral water for 15-30 minutes daily for 10-14 days and it is taken inside twice a day in small sips to 100-150 ml for 14-21 days. Mineral water is used as mineral water, having the following composition: total mineralization - 1.9-2.5 g/dm3, hydrogen carbonate ions - 740-950 mg/dm3, sulfate ions - 90-140 mg/dm3, chloride ions - 500-600 mg/dm3, calcium ions - no more than 15 mg/dm3; magnesium ions - no more than 10 mg/dm3; ions of sodium and potassium - 600-800 mg/dm3, strontium - no more than 25.00 mg/dm3, chromium - not more than 0.50 mg/dm3, zinc - no more than 5.00 mg/dm3, lead - no more than 0.10 mg/dm3, mercury - not more than 0.02 mg/dm3, selenium - not more than 0.05 mg/dm3, vanadium - no more than 0.40 mg/dm3, copper - not more than 1.00 mg/dm3, cadmium - not more than 0.01 mg/dm3, nitrates - not more than 50.00 mg/dm3, nitrites - not more than 2.00 mg/dm3, fluorine - not more than 10.00 mg/dm3, arsenic - no more than 1.50 mg/dm3, phenols - not more than 0.10 mg/dm3, uranium - not more than 1.80 mg/dm3, radium - no more than 5.2×10-7 mg/dm3, organic substances in terms of carbon - 5.00-30.00 mg/dm3. In particular, mineral water can be used from the source of the resort of Saki, the Republic of Crimea, mineral water from the source of the resort of Loutraki, Greece, mineral water from the resort's source in Evpatoria, the Republic of Crimea. Montmorillonite clay Kudrinsky deposit, the Republic of Crimea can be used as bentonite.EFFECT: effective treatment, reducing the risk of recurrence of inflammatory periodontal diseases and conditions after invasive interventions of the oral mucosa.5 cl, 3 ex
Composition for prevention or treatment of chronic obstructive pulmonary diseases containing monoacethyldiglycerol compounds as active ingredient // 2642631
FIELD: pharmacology.SUBSTANCE: compounds of this invention reduce the expression level of CXCL-1, TNF-α or MIP-2, and thus do not have the side effects of the currently used therapeutic agents for chronic obstructive pulmonary disease treatment, are non-toxic and have an excellent therapeutic effect, so that they can be useful as a composition for prevention, treatment and reduction of chronic obstructive pulmonary diseaseseverity.EFFECT: prevention of chronic obstructive pulmonary disease containing monoacetyl diacylglycerin as an active ingredient.10 cl, 6 ex, 8 tbl
Pharmaceutical composition // 2642624
FIELD: pharmacology.SUBSTANCE: version 1 of the composition contains maleate indacaterol in an amount of 20-1200 μg in combination with fluticasone furoate in an amount of 0.5-800 μg or ciclesonide in an amount of 20-800 μg, lactose and optionally one or more pharmaceutically acceptable excipients. Version 2 of the composition contains maleate indacaterol in an amount of 20-1200 μg in combination with fluticasone furoate in an amount of 0.5-800 μg and tiotropium in an amount of 2.25-30 μg, lactose and optionally one or more pharmaceutically acceptable excipients. The composition is in a form suitable for administration once a day.EFFECT: composition according to the invention simplifies the mode of drug administration in the treatment of respiratory, inflammatory or obstructive airway diseases.2 cl, 49 ex

System delivery and regulated expression of paracrine genes for treatment of cardiovascular and other diseases // 2642605
FIELD: medicine.SUBSTANCE: group of inventions can be used to treat heart failure with congestive heart failure (CHF), diabetes or prediabetes in vivo in a patient in need thereof. To this end, a vector is administered to a subject comprising a nucleic acid encoding a paracrine polypeptide or a peptide selected from the group consisting of cardiotonic peptide, urocortin-2 (UCn-2), urocortin-1 (UCn-1), urocortin-3 (UCn-3), brain natriuretic peptide and prostacyclin synthase, wherein the said nucleic acid encoding a paracrine polypeptide or peptide is operably linked to a promoter, wherein the vector is an adeno-associated virus (AAV), and wherein the paracrine polypeptide or peptide is expressed in a cell.EFFECT: group of inventions provides treatment or improvement of CHF, diabetes or prediabetes in a patient.24 cl, 20 dwg, 3 tbl
ethod of conservative treatment of osteochondrosis // 2642253
FIELD: medicine.SUBSTANCE: method includes introducing vitamin B12. According to the invention, vitamin B12 is administered with 0.5% novocaine in the interstitial spaces to a depth up to the yellow ligament at a dose of 500 μg/ml.EFFECT: use of the invention makes it possible to accelerate and prolong analgesia by introducing into the depth to the yellow ligament.1 ex
Spiro-fused piperidine derivatives for application as inhibitors of external medullar layer potassium channel // 2642066
FIELD: pharmacology.SUBSTANCE: invention relates to compounds of formula I .EFFECT: new compounds of formula I are obtained which are inhibitors of the ROMK channel and which can be used in hypertension treatment.11 cl, 5 tbl, 85 ex
ethod for treatment of mouth cavity candidosis with lizobakt and cyclopheron by using removable orthopedic constructions // 2642053
FIELD: medicine; dentistry.SUBSTANCE: invention refers to medicine, namely to dentistry. In method of oral candidiasis treatment in patients with removable orthopedic structures, including correction of the prosthesis basis, as well as treatment of inflamed areas of the soft tissues of the prosthetic bed with a 3 % solution of hydrogen peroxide, followed by application to the treated areas of 10 % methyluracil emulsion, according to the invention, additionally, the lysobact is given topically 1 tablet 3 times a day, slowly dissolving the drug, at the time of using the drug, the orthopedic structures are removed; 1 pill of tsikloferon taken orally once a day 30 minutes before eating; duration of the therapy course is two weeks.EFFECT: method allows to eliminate the phenomena of hyperemia, swelling and soreness, thereby improving the patients life quality with complete or partial absence of teeth.1 cl, 1 tbl
ethod for morphological evaluation of influence of various dosage forms of iron for enternal application on small intestine in experimental animals // 2641979
FIELD: medicine.SUBSTANCE: pathohistological examination of the small intestine tissues is performed. Morphological criteria are determined: desquamation of the mucosal epithelium, necrosis of the mucous membrane, arterial-venous hyperemia, hemorrhage, mucosal edema, hemosiderosis of enterocytes, hemosiderosis of phagocytes. Further, the criteria are scored. The degree of influence of medicinal forms of iron on the small intestine (SPK) is calculated according to the claimed formula. The value of SPK from 0 to 1.2 points inclusive is assessed as a mild injury. SPK from 1.3 to 1.9 points inclusive - as an average injury. SPK from 2.0 to 3.0 points inclusive - as a serious injury.EFFECT: method allows to accurately and simply perform a morphological evaluation of the effect of various medicinal forms of iron for enteral administration on the small intestine in experimental animals by determining the most significant morphological criteria.2 tbl
N-acetyl-l-cysteine for application in extracorporeal fertilization // 2641606
FIELD: pharmacology.SUBSTANCE: invention is a pharmaceutical composition containing N-acetyl-L-cysteine (NAC) alone or together with (2) selenium in the form of selenomethionine and/or (3) melatonin and/or their physiologically acceptable salts and a suitable carrier or an excipient for application in IVF treatment of infertility in a mammal, characterized by a NAC dose of 50-150 mg/kg of body weight administered intravenously or a NAC dose of 30-45 mg/kg of body weight is administered once daily for 1 to 3 days orally, or alternatively, 600 mg of NAC is administered three times a day orally for three consecutive days in a week, followed by four days without drug administration for a total of three months or more before IVF-treatment.EFFECT: higher percentage of live births.1 tbl, 12 cl, 1 dwg
Quinine compounds, method for their production and their medical application // 2641285
FIELD: pharmacology.SUBSTANCE: invention relates to a compound of formula I or a pharmaceutically acceptable salt or optical isomer thereof, wherein, in formula I, n is selected from 1 to 7, R1 means C3-C7 hydrocarbyl, which may be unsubstituted or optionally substituted by halogen, alkoxy, alkoxycarbonyl, heterocyclyl or aryl; R2 is aryl or heteroaryl containing one or more heteroatoms selected from N, O or S which may be unsubstituted or optionally substituted by one or more substituents of halogen, phenyl, -OR6, -SR6, -NR6R7, -NHCOR6, -CONR6R7, -CN, -NO2, -COOR6, -CF3 or linear or branched C1-C4 hydrocarbyl, R6 and R7 can denote a hydrogen atom or linear or branched C1-C4 hydrocarbyl; R3 is hydroxyl, halogen, alkoxy or acyloxy. Alkoxy or acyloxy may be unsubstituted or optionally substituted by halogen, hydroxyl, alkoxy, hydrocarbyl, alkoxyhydrocarbyl, heterocyclyl or aryl; R4 and R5 may or may not be present, and, independently, can mean, without limitation, a substituent such as halogen, hydroxyl, alkoxy, hydrocarbyl, alkoxyhydrocarbyl, heterocyclyl or aryl when these radicals are present. Y is linear or branched C1-C7 alkyl or - (CH2-O-CH2)m-, which may be optionally substituted by halogen, hydroxyl, alkoxy, alkoxyalkyl, unsaturated hydrocarbyl, cyclic hydrocarbyl or heterocyclyl. M is 1-3; X- means an acid residue or hydroxyl, the said compounds having a selective antagonistic effect on the M1 and M3 receptors subtypes, but insignificantly affect the M2 receptor subtype.EFFECT: compound application efficiency increase.24 cl, 5 tbl, 33 ex
Agent for pyoinflammatory processes in soft tissues and mucous membranes // 2641095
FIELD: pharmacology.SUBSTANCE: invention is an agent for treatment of pyoinflammatory processes in soft tissues and mucous membranes in the form of a film that contains benzalkonium chloride, metronidazole, lidocaine hydrochloride, dimethyl sulfoxide, glycerol, sodium salt of carboxymethylcellulose and 5% solution of aminocaproic acid, with components in the agent being in a specific ratio of mass fractions.EFFECT: creation of an effective agent in the form of a film possessing antimicrobial, sorption, analgesic, wound healing and haemostatic action.4 tbl
Application of fullerene c60 aqueous solution as therapeutic agent at atopic dermatitis disease // 2641091
FIELD: pharmacology.SUBSTANCE: invention is application of a therapeutic agent for parenteral administration in atopic dermatitis, which is a water-salt solution consisting of fullerene C60, pluronic F-127 and physiological saline, where the components in the agent are in a certain ratio per ml of solution.EFFECT: reduction of allergic inflammation, skin regeneration improvement.1 tbl, 5 dwg
eans for topical application in complex therapy of oral cavity diseases // 2641056
FIELD: pharmacology.SUBSTANCE: topical means for complex treatment of oral cavity diseases contains ground succinic acid introduced into the oil extract of propolis by suspension type in a weight ratio of 0.5:99.5; while the oil extract of propolis is prepared by extraction of propolis raw frozen at -10°C and ground to a powdered state with a fraction size of 0.05-0.1 mm with sunflower oil refined at room temperature for 5 days at a propolis to extractant ratio of 1:9.EFFECT: means has a strong antioxidant effect, contains no alcohol and irritants, so can be used for application to mucous membranes of the oral cavity in treatment of individuals sensitive to alcohol, or children.2 tbl
ethod for treatment and prevention of reproductive function violations in cows // 2641051
FIELD: veterinary medicine.SUBSTANCE: preparation of the following composition: glucose - 45.0, calcium chloride - 10.0, potassium chloride - 2.0, sodium chloride - 6.0, magnesium chloride hexahydral - 4.0, bidistilled water up to 1000 ml, pH 6, 8-7.5 - is administered to the abdominal cavity three times for 72 hours at a rate of 1 ml per 1 kg of the animal live weight.EFFECT: method allows to improve the reproductive ability of animals.2 tbl, 2 ex
Composition for atopic dermatitis therapy based on fulleren // 2641041
FIELD: medicine.SUBSTANCE: composition includes an aqueous solution of fullerene C60, vaseline, sucrose palmitate, as well as parabens - nipasol and nipagin in a weight ratio of 4:3.78:2.2:0.001:0.001. The final content of fullerene in the composition is 0.005 to 0.012 wt %.EFFECT: invention allows reduction of inflammatory leukocyte infiltration of the epidermis.1 cl

Bandage with prolonged detection of active substances // 2641031
FIELD: medicine.SUBSTANCE: bandages based on polysulphated oligosaccharides showing prolonged release of said active substances, and a process for their preparation are described, wherein the method comprises the step of treating with ethylene oxide. The invention relates to the use of these bandages for wound care and for the treatment and/or prevention of scar formation and skin stretch marks.EFFECT: high release of active substances.16 cl, 4 dwg, 2 ex

Rectal suppositories for prostate treatment containing lysyl-glutamyl-aspartyl-proline tetrapeptide // 2640931
FIELD: pharmacology.SUBSTANCE: invention describes rectal suppositories for treatment of prostate diseases, particularly chronic prostatitis, including chronic abacterial prostatitis (HAP), prostatic hyperplasia, benign prostatic hyperplasia, and for treatment of pre-and postoperative prostate conditions. Suppositories contain lysyl-glutamyl-aspartyl-proline tetrapeptide (0.0003-0.0010 grams), dimethylsulfoxide (0.014-0.05 g) and a base for suppositories in an amount sufficient to produce a suppository weighing 1.0 g.EFFECT: suppositories are stable during storage and highly effective for treatment of prostate diseases.5 cl, 1 dwg, 3 tbl, 6 ex
ethod for lichen planus treatment in oral cavity // 2640930
FIELD: medicine.SUBSTANCE: in addition to conventional therapy, after mucous membrane drying, l-arginine is used as an epithelizing agent in combination with Tysol gel, in a ratio of 5 parts of Tysol to 1 part of l-arginine, applying the first layer of Tysol gel with an applicator brush or a single-bundle brush, then 10-15 seconds after - to 6 layers of Tysol in combination with l-arginine, with a course of 14 days, 2 times a day.EFFECT: method allows to accelerate treatment due to the high adhesion of the drug on the oral mucosa with a reduced drug consumption, absence of systemic side effects and ease of use.1 cl
ethod of treatment of subclinical mastitis of lactating cows // 2640926
FIELD: veterinary medicine.SUBSTANCE: cows are intramammary inserted into the affected udder quarter with the therapeutic agent "Malavit" at a concentration of 15-25%. The specified agent is injected after morning milking in a dose of 20-30 ml once a day within 5-7 days.EFFECT: method provides a new technique for treating latent mastitis of cows by expanding the range of the medicinal agents used.3 ex

Cations of monovalent metals of dry powders for inhalations // 2640921
FIELD: pharmacology.SUBSTANCE: dry powders for treatment of respiratory diseases, consisting of inhaled dry particles, including salts of monovalent metals in quantities of at least 3% of the weight of dry particles and a pharmaceutically active substance, which represents an antibiotic, LABA, LAMA, a corticosteroid or a combination thereof. At that, dry particles in the dry powders are characterized by a volume geometric mean diameter of 5 mcm or less, tundish density between 0.45 g/cm3 and 1.2 g/cm3 and ratio of the volumetric mean geometric diameter measured at a dispersion pressure of 1 bar divided by the volumetric mean geometric diameter measured at a dispersion pressure of 4 bar is less than 1.5. Also, dry powders application for the manufacture of drugs for treatment and prevention of respiratory diseases and their exacerbations are disclosed.EFFECT: due to high dispersibility of dry particles, the group of inventions allows treatment and prevention of respiratory diseases through dry powders inhalation into the lungs of the patient, using only the energy of inhalation, without application of carrier particles or active inhalers.22 cl, 20 dwg, 28 tbl, 17 ex
Electrolyte laxative // 2640920
FIELD: pharmacology.SUBSTANCE: invention relates to laxative compositions, which contain: from about 2 to about 37 g of water-soluble sodium salt, water-soluble potassium salt; erythrite, xylose, xylotriose or their equivalents; bisoxatin (or 2,2-bis(4-hydroxyphenyl)-2H-benzo[b][1,4]oxazine-3(4H)-on) or bisoxatin acetate or its equivalent.EFFECT: minimizing side effects.35 cl, 4 ex
Peroral compositions containing ester 17- hydroxyprohesteron, and corresponding methods // 2640912
FIELD: pharmacology.SUBSTANCE: bioavailable peroral dosage forms are proposed, containing 17-hydroxyprohesteron caproate in the form of particles with an average diameter of 50 micron or less, as well as corresponding methods. Said peroral dosage forms can be prepared for pregnancy maintenance and contain a therapeutically effective amount of 17-hydroxyprohesteron caproate and pharmaceutically acceptable carrier. At least 20 wt % of 17-hydroxyprohesteron ester dose escape from said peroral dosage forms during determination using a device for dissolution of 2nd type in accordance with USP in 900 ml of deionised water with 0.5% (wt/vol) of sodium lauryl sulphate at 50 rpm and 37°C in 60 minutes.EFFECT: peroral form with high bioavailability.54 cl, 3 dwg, 54 ex, 14 tbl
Systems and compositions for postprocedure skin care and methods of application thereof // 2640504
FIELD: pharmacology.SUBSTANCE: invention is a topically-applied wound healing composition consisting of the following components: aluminium sulfate tetradecahydrate present in an amount from about 40.0 wt % to about 55.0 wt % on the basis of the weight of the topically-applied wound healing composition, calcium acetate monohydrate present in an amount from about 28.0 wt % to about 39.0 wt % on the basis of the weight of the topically-applied wound healing composition, common oat grain protein present in an amount from about 0.01 wt % to about 20 wt % on the basis of the weight of the topically-applied wound healing composition, soy protein in an amount from about 0.01 wt % to about 20 wt % on the basis of the weight of the topically-applied wound healing composition, whey protein present in an amount from about 0.01 wt % to about 20 wt % on the basis of the weight of the topically-applied wound healing composition, chitosan present in an amount from about 0.25 wt % to about 50 wt % on the basis of the weight of the topically-applied wound healing composition, potassium sorbate present in an amount from about 0.25 wt % to about 10 wt % on the basis of the weight of the topically-applied wound healing composition and dextrin present in an amount from about 5 wt % to about 50 wt % on the basis of the weight of the topically-applied wound healing composition.EFFECT: effective healing of postprocedure wounds on the skin, high stability.23 cl, 4 dwg, 8 tbl, 4 ex
Composition for atopic eczema prevention or treatment containing monoacetyldiacyl glycerine compound as active ingredient // 2640503
FIELD: pharmacology.SUBSTANCE: inventions represent: a pharmaceutical composition, a composition of the functional product of therapeutic nourishment, quasimedicine composition for preventing or treating atopic eczema containing monoacetyldiacyl glycerine of formula 2 , as an active ingredient. The invention also includes a method of preventing or treating atopic eczema, comprising of administration to a non-human patient any of the compositions described above.EFFECT: monoacetyldiacyl glycerine of this invention effectively inhibit the secretion of IL-4 and IgE, without side effects, they are non-toxic and exert an express therapeutic effect.6 cl, 8 dwg, 1 tbl, 5 ex

Combination treatment of cancer // 2640485
FIELD: pharmacology.SUBSTANCE: proposed: a combination for application as a drug for cancer treatment, containing: (S)-4-amino-N-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363) or a salt thereof with an androgen receptor signal modulator selected from 4-{3-[4-cyano-3-(trifluoromethyl)-phenyl]-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl}-2-fluoro-N-methylbenzamide (MDV-3100) and N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)-sulfonyl]-2-hydroxy-2-methylpropanamide (bicalutamide) or a salt thereof, a set of these components for application in cancer treatment (versions).EFFECT: greater inhibition of tumour growth by combining the said compound against monotherapy of castration-resistant prostate cancer, the combination showed good tolerability.9 cl, 3 dwg, 1 tbl
odulators of atp-binding cartridge transporters // 2640420
FIELD: pharmacology.SUBSTANCE: invention relates to compounds of the formula II , where R is H, OH, OCH3, or two R taken together form -OCH2O- or -OCF2O-; R1 is H or up to two C1-C6alkyls; R2 is H or halogen; and R3 is H or C1-C6 alkyl; R3 is H or C1-C6 alkyl; Y is O or NR4; and R4 is H or C1-C6 alkyl, and their pharmaceutical compositions useful as modulators of ATP-binding cassette ("ABC") transporters, or fragments thereof, including a cystic fibrosis transmembrane conduction regulator ("CFTR"). This invention also relates to methods for treatment of diseases mediated by ABC transporters using the compounds of the invention.EFFECT: increased efficiency of treatment.19 cl, 2 tbl, 1 ex
Antiseptic composition intended for application in oral cavity, for treatment of oral mucositis // 2640301
FIELD: pharmacology.SUBSTANCE: application of antiseptic composition is proposed. The composition is in the form of a solution for local administration in the mouth cavity, and the composition contains one antiseptic agent, isolated from a group, consisting of hydrogen peroxide and carbamide peroxide and their mixture, cetylpyridinium chloride, or their mixtures; ether oil, isolated from eugenol; phenolic antiseptic agent, isolated from vapour chlorophenol; agent having antiseptic properties, isolated from camphor; plant extract, isolated from wild chamomile, and auxiliary substances. In addition, in this invention a method for treatment of oral mucositis and stomatitis is proposed. It is associated with anticancer therapy, including production of the antiseptic composition and administration of the composition, designed for use in mouth cavity, in the mouth cavity of the patient, who needs it.EFFECT: effective prevention and improvement of the condition of the patient, suffering from oral mucositis or stomatitis, without any side effects.9 cl, 5 ex, 1 tbl
New compounds // 2640200
FIELD: pharmacology.SUBSTANCE: invention relates to a new compound of the formula (I) or a pharmaceutically acceptable salt thereof having interferon α (IFN-α) and tumour necrosis factor α (TNF-α) inducer properties. The compounds may be useful as vaccine adjuvants. In the formula (I) R1 is n-C3-6alkyl; R2 is hydrogen or methyl; R3 is hydrogen or C1-6alkyl; m is an integer having a value of 1 to 4.EFFECT: compounds can be used for treatment of allergic diseases and inflammatory conditions, for example, allergic rhinitis and asthma, infectious diseases and cancer.15 cl, 7 ex
Anhydrous powder and liquid particles // 2640184
FIELD: chemistry.SUBSTANCE: powder is provided for use in personal care compositions containing core/shell particles having an average particle size of less than 1000 mcm, each of the particles comprising: 1) a liquid core that is substantially free of water and contains a polar liquid with a surface polarity of, at least, 24% and 2) a shell containing hydrophobic particles.EFFECT: improved powder properties.12cl, 3 ex, 3 tbl, 2 dwg
Liquid marker for determination of respiratory epithelial clearance speed of nasal mucosa and maxillary sinus // 2640174
FIELD: medicine.SUBSTANCE: liquid marker for determination respiratory epithelial clearance speed of the nasal mucosa and maxillary sinus contains methylene blue, anesthesin, saccharin, sodium laurisulfate and distilled water. The ingredients are used in the declared amounts.EFFECT: application of the invention allows to determine the speed of mucus transport over the surface of the mucosa and gives a characterization of the human respiratory epithelial clearance system as a whole.1 ex
Application of thr-lys-pro-arg-pro-gly-pro peptide (selank) for toxic hepatitis prevention and treatment // 2640133
FIELD: medicine.SUBSTANCE: application of a peptide of the formula Thr-Lys-Pro-Arg-Pro-Gly-Pro (selank) as a hepatoprotective agent is proposed. The method of the invention comprises administration of a drug based on the heptapeptide of the general formula Thr-Lys-Pro-Arg-Pro-Gly-Pro (selank) by application to the mucosa.EFFECT: application of the inventions allows to reliably reduce lethality, cytolysis level, metabolic disturbances, increase the activity of the detoxification process, prevent the development of significant changes in liver morphology and cytoarchitectonics.2 cl, 9 tbl, 2 ex

In situ crosslinked polymeric compositions and methods for them // 2640084
FIELD: medicine.SUBSTANCE: invention refers to a gel matrix composition for treatment of bleeding wounds consisting of: a) 0.1-5 wt % of sodium alginate; b) 2-25 wt % of chitosan; c) water - the rest.EFFECT: rapid healing of the tissue on which the proposed composition is applied, which is also easily applied and easily removable from the application site.12 cl, 12 dwg
Dermatological reparative means and its external use for skin care, prevention and treatment of skin lesions of various etiology // 2640026
FIELD: medicine.SUBSTANCE: invention is a dermatological reparative means containing zoosterol, lightly crosslinked acrylic polymers, representing acrylic acid homopolymer esters, cross-stitched by allyl saccharose, allyl pentaerythritol or divinyl glycol, preservatives, caustic soda and distilled water, at that, components are at a specific ratio in wt %.EFFECT: increased effectiveness of action due to high adhesion to the skin surface, increased duration of agent action, shortened duration of the healing process, enhanced regeneration of the affected skin, lack of toxicity, and suppression of external allergic reactions.4 cl, 3 tbl
Composition for topical application, containing glycerin and tannin // 2640020
FIELD: pharmacology.SUBSTANCE: invention relates to a topical formulation for treatment of skin and mucosal infections comprising glycerin in an amount of 30 to 99.99% v/v and plant proanthocyanidins; to a method for maintaining of a glycerin film on a biological surface by preparing the formulation and its application to a biological surface; to a method for skin and mucosal infections treatment, comprising the step of composition application; to a method for production of the claimed composition.EFFECT: formation of a long-term high-osmotic film on damaged surfaces, thereby keeping the lesions clean from all free contaminants.11 cl, 9 dwg, 11 ex

ethod for degenerative-dystrophic spine diseases (dorsopathies) treatment // 2640001
FIELD: medicine.SUBSTANCE: method includes three main steps. The first is the compensatory stage, which uses known methods of combined drug treatment, aimed at a transfer to a subacute or compensated stage of the disease. At the recovery stage, chondroptic peptide bioregulators VitOrgan are introduced according to a certain scheme. The bioregulators are injected slowly by jets based on 0.5% novocaine solution or saline solution mixed with 10 ml of 30% sodium thiosulfate solution up to 20 ml. Or dropwise introduction is performed, while the drug is dissolved in 100 or 200 ml of saline solution, or 200 ml of Reamberin, introduction rate is 50-60 drops per minute. Intravenous drugs administration is combined with subcutaneous or intramuscular administration of peptide bioregulators, including in combination with vascular and vasoactive agents. The rehabilitation phase involves the use of techniques such as massage, manual and osteopathic treatment techniques, physical therapy, therapeutic exercises, as well as methodologies aimed at body purification. Peptide bioregulators, vasoactive drugs and chondroprotectors are also used.EFFECT: method allows to significantly accelerate the process of patient recovery and achieve a lasting result.23 cl, 2 ex, 4 dwg
Phenyl derivative // 2639875
FIELD: pharmacology.SUBSTANCE: invention relates to a compound of the general formula (I) having a high antagonistic activity with respect to human S1P2, and can be used to prepare a drug for treatment of a disease mediated by S1P2, such as a disease caused by vasoconstriction, fibrosis and respiratory disease.EFFECT: compound application efficiency increase.14 cl, 2 tbl, 9 ex
Hetero-aromatic methylic derivative of cyclic amine // 2639869
FIELD: chemistry.SUBSTANCE: invention relates to a compound represented by the formula (IA), where X1 and X2 are the same or different and are a nitrogen atom or a CH group; Y is any structure from the following group of formulas (a); n is 1 or 2; R1 is a hydrogen atom, a halogen atom or a C1-6 alkyl group; R2 is a triazolyl group or a pyrimidinyl group; R3 is a hydrogen atom or a halogen atom; and R4 is a hydrogen atom or a C1-6 an alkyl group; or a pharmaceutically acceptable salt thereof. The invention also relates to a compound represented by the formula (I), where X1 and X2 are the same or different and are a nitrogen atom or a CH group; any one of Y1 and Y2 is a nitrogen atom, and the other is CH; n is 1 or 2; R1 is a hydrogen atom, a halogen atom or a C1-6 alkyl group;R2 is a triazolyl group or a pyrimidinyl group; R3 is a hydrogen atom or a halogen atom; and R4 is a hydrogen atom or a C1-6 alkyl group; or a pharmaceutically acceptable salt thereof. The compounds of the invention are intended for the production of a pharmaceutical composition having antagonistic activity against OX1 and OX2 orexin receptors.EFFECT: hetero-aromatic methyl derivative of cyclic amine, which has antagonistic activity against OX1 and OX2 orexin receptors.9 cl, 6 tbl, 85 ex
ethod for lymphotropic therapy of donor skin wounds // 2639847
FIELD: medicine.SUBSTANCE: method includes subcutaneous injection of free autodermoplasty 32 ED lidase diluted in 2 ml of a 2% solution of lidocaine 1 hour before the operation, then after 5-10 minutes 4 ml of etamzilate are administered 1 time per day. Then, after 24 hours, the injection course is carried out at the same spot according to the scheme: 32 units of lidase diluted in 2 ml of a 2% solution of lidocaine, then after 5-10 minutes 5 ml of actovegin is injected once every two days in the amount of 4 injections.EFFECT: use of the invention allows to reduce intraoperative blood loss, contributes to the prevention of bleeding and formation of hematomas in the donor site wound area in the postoperative period, accelerates epithelization and formation of a more delicate scar.1 ex
ethod for early rehabilitation of patients after surgeries related to benign diseases of digestive system // 2639581
FIELD: medicine.SUBSTANCE: complex impact in sanatorium-resort conditions is provided: on the background of fractional diet and mineral alkalescent water intake monitoring send intestine cleaning performed, for completion of which 200 ml of a solution containing highly-pure apple pectin in mineral water is injected, in rinse-free days microclysters with Biovestin probiotic are provided and laser exposure is provided daily at 4 points in the area of postoperative joints.EFFECT: method allows to shorten the period of medical and social rehabilitation.2 ex
Bifunctional peptide // 2639573
FIELD: biotechnology.SUBSTANCE: invention relates to the field of biotechnology, specifically to the bifunctional peptide capable of activating collagen synthesis and inhibiting matrix metalloproteinase production, and can be used in medicine and cosmetology. Bifunctional peptide has a sequence of three peptide regions a, b, and c. The first region A is hexapeptide, repeated at least three times, capable of communicating with an elastin-binding receptor protein to stimulate collagen synthesis. The second region B is tetrapeptide capable acting as a competitive inhibitor of urokinase protease and cleaving by the said protease. The third region C is tripeptide that occupies at least one active site of matrix metalloproteinases to permit inhibition of these proteinases.EFFECT: invention allows to effectively stimulate collagen synthesis and inhibit the production of matrix metalloproteinases for treatment of chronic cicatricial diseases, sores, or ulcers for skin tissue recovery or regeneration and for skin anti-aging.18 cl, 7 ex, 8 dwg

Peptidomimetic macrocycles and their application // 2639523
FIELD: biotechnology.SUBSTANCE: peptidomimetic macrocycle is proposed that binds to the Growth-Hormone-Releasing Hormone (GHRH) receptor and its use. The peptidomimetic macrocycle proposed has a structure as shown in the formula.EFFECT: peptidomimetic macrocycle has improved biological activity, stimulates the production and release of growth hormone and can be used to increase lean muscle mass in the patient, to reduce adipose tissue in the patient, to treat muscle atrophy, lipodystrophy, growth hormone, gastric paresis, or short-term syndrome guts in a patient.31 cl, 11 dwg, 5 tbl, 4 ex
ethod for intestinal flora stimulation // 2639490
FIELD: medicine.SUBSTANCE: at that, this composition is adapted for enteral administration to infants. The composition comprises at least one microorganism and at least non-digestible galactooligosaccharides, wherein the said microorganism is at least one species of Bifidobacteria selected from the group consisting of Bifidobacterium breve, Bifidobacterium infantis, Bifidobacterium bifidum, Bifidobacterium catenulatum, Bifidobacterium adolescentis and Bifidobacterium longum.EFFECT: invention allows to stimulate healthy development of intestinal flora in these infants.9 cl, 2 tbl, 6 ex
eans for intravital skin whitening near blue eyes // 2639485
FIELD: cosmetology.SUBSTANCE: means is presented that is characterized by including sodium hydrogen carbonate at a temperature of 45°C, hydrogen peroxide, lidocaine hydrochloride and water for injection, the components in the means are in a certain proportion in wt %. Local hyperthermic alkaline steaming, discoloration and loss of skin sensitivity with a warm bruise bleach solution and local anaesthetic easily penetrating the skin, in conditions that exclude skin piercing with an injection needle, additional blood vessel damage, interstitial bleeding, haemorrhage, hematoma formation, bruising, inflammation, abscess and sepsis.EFFECT: non-invasive discolouration and anaesthesia of facial skin with bruises and blue eyes.1 cl
ethod for obtaining of preparation for prevention of digestive tract infections in agricultural birds and preparation obtained by this method // 2639484
FIELD: veterinary medicine.SUBSTANCE: in the proposed method comprising premixing Saccharomyces cerevisiae yeast biomass with enzymatic preparations of CelloLux-F or CelloLux-A, Protosubtilin and water, mechanical activation of the mixture, according to the invention, mechanical activation of the mixture is carried out in centrifugal-roller, ring, vibrational centrifugal, vibration type activators; in addition, inorganic abrasive material or inorganic abrasive materials are added to obtain the preparation, with the following ratio of components in the mixture, wt %: enzymatic preparation CelloLux-F or CelloLux-A - 0.1-8; enzymatic preparation Protosubtilin - 0.1-8; inorganic abrasive material - 0.3-11 or inorganic abrasive materials - 0.1-11; water - 0.5-5; yeast biomass - the rest. The claimed preparation is obtained by the claimed method.EFFECT: group of inventions provides a preparation with effects on microflora of the gastrointestinal tract of agricultural birds and absorbent properties due to the presence of mannoproteins.4 cl, 9 tbl, 10 ex

Application of growth hormone fragments // 2639474
FIELD: medicine.SUBSTANCE: subject receives an effective amount of peptide with a length from 8 to 50 amino acid residues containing amino acid residues of 182-189 human growth hormone, or growth hormone of another kind of animal, or a site of any of SEQ ID NO:1-41. This peptide does not contain the growth hormone domain responsible for IGF-1 production. A method for stimulation of chondrocytes or cartilaginous tissue formation or recovery is also provided.EFFECT: treatment of a state associated with chondrocytes of cartilage function failure by stimulating the production of collagen and proteoglycan in cartilage tissue.22 cl, 16 dwg, 9 ex
ethod for acute radiation esophagitis treatment // 2639463
FIELD: medicine.SUBSTANCE: for treatment of acute radiation esophagitis during radiation therapy, 25-30 g of "Koleteks gel DNA-l" is taken orally before a radiation therapy session. At that, during the radiotherapy session, placement of the "Kolegel-DNA-disk" material in the oral cavity is assigned with complete gradual dissolution. After completion of radiation therapy, inhalations with "Koleteks-Beta", hydrogel which is mixed with inhalation solution "Fluimucil" and water at a ratio of 3:5:2 accordingly are prescribed 2 times a day, 5-10 min. within 5-7 days. Inhalations are continued for the next 3-4 months, 5-7 days per month with a break of 20-25 days.EFFECT: invention reduces the frequency and severity of early and late radiation reactions in patients.3 ex
ethod for endothelioprotection in adma-similar gestosis model by arginase ii inhibitor // 2639415
FIELD: pharmacology.SUBSTANCE: method involves reproduction of gestosis in laboratory pregnant Wistar rats by daily intraperitoneal administration of the NO-synthase inhibitor L-NAME from day 14 to day 20 of pregnancy at a dose of 25 mg/kg/day. At that, correction of endothelial dysfunction is performed daily by intragastric administration of a selective inhibitor of arginase II-KUD975. Inhibitor administration is performed 30 minutes prior to the administration of L-NAME at a dose of 1 mg/kg of animal body weight.EFFECT: pronounced correction of dysfunction under the conditions of specific mechanisms of the pathological process in pregnant women, with elimination of side effects typical for low- and nonselective arginase inhibitors.1 ex